Infection with human papillomaviruses (HPV) requires the minor capsid component L2, which plays an essential role in directing appropriate endosomal trafficking. Previous studies have indicated an infection route involving multi-vesicular bodies (MVBs), and an essential element in their biogenesis is the ESCRT machinery. Here we show that the ESCRT component TSG101 is required for optimal infection with both HPV-16 and BPV-1, with loss of TSG101 resulting in a decrease in viral infection, whereas overexpressed TSG101 increases rates of infection. We find that L2 proteins from multiple PV types interact with TSG101 and show that this interaction contributes to an alteration in the subcellular distribution of L2. In addition, TSG101 can modulate the levels of L2 polyubiquitination. These results demonstrate that TSG101 plays an important part in infection with diverse PVs, and suggests that trafficking of HPV through the ESCRT machinery and MVBs is part of infectious virus entry.
Introduction
Human Papillomaviruses (HPVs) are small non-enveloped viruses that contain an 8 kb DNA genome encased within an icosahedral capsid. They infect epithelial cells and their life cycle is intimately linked to the differentiation of the infected epithelium (Doorbar, 2007) . Whilst HPVs predominantly only cause benign epithelial lesions, a subset of 12 types are defined as cancer-causing, with tumours arising in the cervix, other anogenital regions, and in the head and neck. Of these types, HPV-16 is probably the most important, and is responsible for over 60% of all cervical cancers world wide (zur Hausen, 1996; Bouvard et al., 2009) .
Papillomaviruses (PVs) encode two structural proteins: the major capsid protein L1, and the minor capsid protein L2. It is well established that the L1 protein alone can self assemble into virus-like particles (VLPs); however, such particles are noninfectious and L2 is required for the correct encapsidation of the viral genome and for infectious viral entry into the host cell (Pereira et al., 2009 ). The PV viral life cycle is tightly connected to the differentiation program of the infected stratified epithelium. PV infection requires the presence of receptors such as heparin sulphate, proteoglycans and α integrin (Joyce et al., 1999; Giroglou et al., 2001; Shafti-Keramat et al., 2003; Dasgupta et al., 2011) . The route by which PVs enter basal cells is diverse and appears to depend upon the virus type: for example, BPV is reported to use clathrin-mediated endocytosis (Laniosz et al., 2008) , HPV-31 a caveolin-dependent mechanism (Smith et al., 2007) , and HPV-16 a novel clathrin-and caveolin-independent pathway (Spoden et al., 2008; Schelhaas et al., 2012; Scheffer et al., 2013; Spoden et al., 2013) . Virus capsids disassemble in the late endosomes and/ or lysosomes in a pH-dependent manner, and the subsequent transport of the viral DNA to the nucleus is facilitated by the minor capsid protein L2 (Day et al., 1998; Florin et al., 2002) . This occurs through a pathway that involves lysozomal escape of the L2-DNA complex, in part due to the ability of L2 to interact with components of the cellular sorting machinery, such as sorting nexin 17 (Bergant-Marušič et al., 2012) . The L2-DNA complex then traffics toward the nucleus through a pathway that requires Dynein-mediated transport Schneider et al., 2011) and accumulates in the trans-Golgi network (Day et al., 2013) . Following nuclear envelope breakdown in mitosis the L2-DNA complex can then enter the nucleus (Pyeon et al., 2009) , where it is found in close proximity with PML bodies, and where viral gene expression is believed to initiate (Day et al., 2004) . The viral genome replicates at a low level in the basal layers of the epithelium, where expression of the non-structural proteins begins, while high copy-number productive replication Contents lists available at ScienceDirect journal homepage: www.elsevier.com/locate/yviro and expression of the structural proteins take place in the differentiating cells of the more superficial layers, ultimately leading to the assembly of new infectious virus particles (Doorbar et al., 2012 ). Mature viron particles are then produced and released from the terminally differentiated suprabasal cells (Doorbar, 2007) .
During PV infection, endosome acidification is an important element for successful viral infection (Kamper et al., 2006; Smith et al., 2008; Dabydeen and Meneses, 2009 ). Recent studies have also shown that HPV-16 pseudovirions (PsVs) are found within the multivesicular bodies (MVBs) of late endosomes (Schelhaas et al., 2012) . MVBs play an essential role in endosomal/lysozomal cargo sorting and are major determinants in deciding whether cargoes go for recycling or lysozomal degradation (Huotari and Helenius, 2011; Katzman et al., 2002) . A critical element in this process is the endosomal sorting complex required for transport (ESCRT) machinery (Saksena, et al., 2007) . Since HPV was shown to be present within MVBs during infection, we were interested in determining whether an essential component of the ESCRT machinery, TSG101, is involved in the PV infectious entry pathway.
Results

TSG101 is required for efficient HPV-16 infection
Previous studies have shown the potential involvement of MVBs during the HPV infection process, with accumulation of HPV particles within MVBs being observed in the later stages of infection (Schelhaas et al., 2012) . Since a critical element in the biogenesis of these bodies are the ESCRT complexes, especially the TSG101 protein, we were interested in determining whether TSG101 might have any role to play during HPV infection. To investigate this we performed a series of infection assays in HaCaT cells using HPV-16 pseudovirions (PsVs) carrying a luciferase reporter gene. Prior to infection the cells were transfected either with an siRNA against TSG101, which forms a major component of the ESCRT-1 complex, or with siRNA against HPV-18 E6/ E7 as a control. The results obtained are shown in Fig. 1 and demonstrate that loss of TSG101 expression significantly reduces the infection efficiency of HPV-16 PsVs. Statistically significant reductions of around 40% were consistently observed. This can be compared with the reduction of around 70% seen upon ablation of SNX17 (data not shown), which is also known to be required for efficient HPV infection (Bergant-Marušič et al., 2012) .
To determine whether TSG101 was also required for infection with other Papillomaviruses, we repeated the assays using BPV-1 PsVs and, for comparison, the unrelated Merkel Cell Polyoma Virus (MCV) PsVs. The results in Fig. 1 show that efficient BPV-1 infection also requires TSG101. Interestingly, loss of TSG101 appears to have no major effect upon the infection efficiency of MCV PsVs, demonstrating that the loss of TSG101 does not perturb endosomal-lysozomal transport processes in general and indicating that the TSG101 requirement is specific for PV infection.
Having shown that loss of TSG101 could reduce infection with HPV, we then performed a series of studies to determine whether TSG101 overexpression could likewise increase rates of infection with HPV-16 PsVs. HaCaT cells were transfected with TSG101 expression plasmids and then infected with HPV-16 PsVs. After 24 h, infection was monitored by measuring luciferase activity and the results obtained are shown in Fig. 1C . As can be seen, increasing amounts of TSG101 (shown in Fig. 1D ) resulted in a statistically significant increase in the α-actinin efficiency of infection with HPV-16 PsVs. Taken together, these results suggest that the ESCRT-1 component TSG101 is involved in the HPV infection process.
L2 interaction with TSG101 is conserved across multiple papillomavirus types
We were next interested in determining how TSG101 might be involved in HPV infection. To do this we first analyzed whether HPV-16 virion components L1 and L2 could interact with TSG101. These were expressed as GST fusion proteins and used in pulldown assays using in vitro translated radiolabelled TSG101. The results in Fig. 2A demonstrate strong interaction between GST-16L2 and TSG101, but little or no interaction between GST-16L1 and TSG101. The assay was also performed using TSG101 derived from HEK293 cells transfected with a TSG101 GFP expression plasmid. As can be seen from Fig. 2B , HPV-16 L2 also interacts with cell-derived TSG101. Furthermore the interaction also appears to be somewhat cold-sensitive, with significantly stronger interaction at room temperature than at 4 1C.
The above infection studies indicate a role for TSG101 in infection with HPV-16 and with BPV-1. We next investigated whether the L2 proteins from diverse PVs could likewise interact with TSG101. GST-L2 fusion proteins derived from BPV-1, SfPV-1, HPV-11 and, for comparison, HPV-16, were purified and used in pull-down assays with in vitro translated, radiolabelled TSG101. The results in Fig. 2C demonstrate very similar levels of association between TSG101 and the L2 proteins from diverse PV types, suggesting that L2-TSG101 interactions are highly conserved across multiple PV types.
Finally we wanted to determine whether HPV-16 L2 could also associate with endogenous TSG101 in vivo. To do this HEK293 cells were transfected with GFP-tagged HPV-16 L2 alone, or in combination with GFP-tagged TSG101. After 24 h the cells were harvested and cell extracts immunoprecipitated with anti-TSG101 antibody, or as a control, with anti-HA antibody. Co-immunoprecipitating HPV-16 L2 was then detected by Western blotting using polyclonal rabbit anti-HPV-16 L2 antibody. The results in Fig. 3 demonstrate a strong interaction between over-expressed HPV-16 L2 and TSG101, as would be expected. However, a clear association can also be seen between endogenous TSG101 and the ectopically expressed HPV-16 L2, whereas no L2 was detected following immunoprecipitation with the anti-HA control antibody. These results demonstrate that HPV-16 L2 can also associate with endogenously expressed TSG101 in vivo.
Identification of the HPV-16 L2 region required for interaction with TSG101
To identify the region of L2 that is responsible for binding TSG101, we generated a series of deletion constructs of HPV-16 L2 which are shown schematically in Fig. 4A . These were HA/Flag tagged and transfected into HEK293 cells, together with GFP-tagged TSG101. After 24 h the cells were harvested and immunoprecipitated using anti-HAconjugated agarose beads. Co-immunoprecipitating TSG101 was then detected by Western blotting with anti-TSG101 antibody. The results shown in Fig. 4B define a region of the L2 protein spanning residues 319-348 as important for association with TSG101, since the construct containing only residues 1-319 is impaired in TSG101 interaction, whereas the 1-348 construct has wild type levels of association. However, residues between 192 and 319 also seem to be involved, since only the HPV-16 L2 1-192 mutant has lost all ability to associate with TSG101.
HPV-16 L2 colocalizes with TSG101
Having shown that TSG101 interacts strongly with HPV-16 L2 we were next interested in determining where the interaction occurs within the cell. To do this, HaCaT keratinocytes were transfected with FLAG-HA-tagged HPV-16 L2 expression plasmid and a GFP-tagged TSG101 expression plasmid. For comparison we also included the HPV-16 L2 deletion mutant spanning residues 1-192, which was shown above to be defective in TSG101 recognition. After 24 h the cells were fixed and stained and the patterns of L2 and TSG101 expression ascertained by immunofluorescent staining and confocal microscopy. The results obtained with wild type HPV-16 L2 and TSG101 are shown in Fig. 5A and demonstrate that L2 normally has a predominantly nuclear pattern of expression, consistent with previous studies, whilst TSG101 displays a largely cytoplasmic pattern of expression, with evidence of clearly defined dot-like structures, consistent with it being localized to late endosomal/lysozomal compartments. When L2 and TSG101 are co-expressed, TSG101 remains predominantly cytoplasmic, and likewise the bulk of L2 remains within the nucleus. However, there is also a significant accumulation of L2 with TSG101 in the dot-like structures found within the cytoplasm. In contrast, the HPV-16 L2 mutant (Fig. 5B) , that has also lost the carboxy terminal nuclear localization signal (NLS) (Darshan et al., 2004; Mamoor et al., 2012) , shows a diffuse pattern of expression throughout the cell. Most importantly, this pattern remains unchanged in the presence of ectopically expressed TSG101, and no apparent co-localisation is seen, which correlates with the inability of this mutant to interact with TSG101. Similar results were also seen in U2OS cells (data not shown). These results demonstrate that L2 can co-localize with TSG101 in late endosomal/lysozomal compartments.
TSG101 modulates L2 ubiquitination
One of the major functions of TSG101 is to interact with monoubiquitinated proteins and to protect them from further polyubiquitination (Burgdorf et al., 2004) . We were therefore interested in investigating whether TSG101 might be able to modulate the ubiquitination of HPV-16 L2. To do this HEK293 cells were transfected GFPtagged HPV-16 L2, GFP-tagged TSG101 and HA-tagged ubiquitin. After 24 h cells were either treated or not with MG132 to rescue any proteins from proteasome-mediated degradation, and ubiquitinbound proteins were immunoprecipitated using anti-HA conjugated agarose beads. Ubiquitinated L2 was then detected by Western blotting using anti-L2 antibody. The results obtained are shown in Fig. 6 and demonstrate that L2 is subject to a significant level of poly-ubiquitination. Interestingly, this does not change significantly in the presence of MG132, suggesting that ubiquitinated L2 is not a significant substrate for the proteasome. Most importantly, in the presence of TSG101 there is a dramatic decrease in the levels of polyubiquitinated L2, however with no major change in total L2 levels. These results indicate that one consequence of the interaction between TSG101 and L2 is a reduction in the level of polyubiquitinated L2.
Discussion
Infection with HPV requires endocytic uptake and subsequent acidification of the endosome, accompanied by viral uncoating. During this process, virus particles can be seen in MVBs (Schelhaas et al., 2012) , which play a role during late endosome maturation (Huotari and Helenius, 2011; Katzmann et al., 2002) , suggesting that steps involved in MVB formation might play a part in the HPV infection process. An important element in the maturation of MVBs is the ESCRT complex, which recognizes and sorts ubiquitinmodified cargoes into the MVBs. We therefore reasoned that this complex might be involved in HPV infection and to assess this we analyzed the role of the major ESCRT component TSG101. We find that, upon loss of TSG101 expression, there is a significant decrease in the levels of infection with HPV-16 PsVs. Likewise, overexpression of TSG101 increases the levels of infection with HPV-16 PsVs. Interestingly, this appears to be important also for BPV, suggesting that the role of TSG101 in PV infection is conserved across diverse PV Fig. 3 . HPV-16 L2 can associate with endogenous TSG101 in vivo. HEK293 cells were transfected with HPV-16L2 GFP and TSG101 GFP together, or HPV-16L2 GFP and pCDNA alone. After 24 h the cells were harvested and cell extracts immunoprecipitated using anti-TSG101 antibody and protein A-conjugated sepharose beads. As a control, lysates from cells transfected with HPV-16L2 GFP alone were divided and immunoprecipitated using anti-TSG101 or anti-HA antibody as a control. Co-immunoprecipitating L2 was then detected by Western blotting using rabbit anti-HPV-16 L2 antibody (top panel). The two lower panels show the inputs for L2 and TSG101. Note very strong co-immunoprecipitation when L2 and TSG101 are overexpressed, but still readily detectable co-immunoprecipitating L2 when in the presence of endogenous TSG101. types. Based on these results it is tempting to suggest that the ESCRT machinery is involved in the HPV infection process, although TSG101 has other activities unrelated to this. However preliminary experiments in which the ESCRT component Vps4 is ablated, also results in a reduction in HPV-16 PsV infection (data not shown), indicating that the ESCRT machinery is indeed required. Obviously further studies are required to investigate this further.
In order to investigate how TSG101 might impact on PV infection, we first investigated the ability of TSG101 to recognize components of the HPV capsid. We found that HPV-16 L2 could interact strongly with TSG101, whereas HPV-16 L1 did not. Extending these studies to L2 proteins derived from different PVs, we could show that the ability to interact with TSG101 is conserved across a wide evolutionary spectrum of PV types, ranging from SfPV and BPV to HPV-16 and HPV-11. This is consistent with the observed effects on infection processes, where BPV also required TSG101 for optimal levels of infection. We also mapped the site of TSG101 interaction on HPV-16 L2, and defined a short stretch of amino acids spanning residues 319-375 as being important for the interaction. Interestingly, this region of L2 is highly conserved through evolution, confirming the highly conserved nature of this interaction.
Previous studies have shown that TSG101 is expressed primarily within endosomal/lysozomal compartments, whilst L2 is predominantly nuclear. Therefore to investigate how L2 and TSG101 might interact in vivo, we performed a series of immunofluorescence analyses on cells co-expressing HPV-16 L2 and TSG101. Whilst neither protein induced a dramatic alteration in the other's pattern of expression, it was quite striking that a significant proportion of L2 became relocalized and was found in close proximity with TSG101 in the endosomal/lysozomal structures within the cytoplasm. The specificity of these effects was further confirmed using a mutant of L2 that could not interact with TSG101. The expression pattern of this mutant, although much more diffuse and cytoplasmic than that of the wild type L2, which is consistent with a loss of the carboxy terminal NLS (Darshan et al., 2004; Mamoor et al., 2012) , was completely unaffected by co-expression of TSG101. These results suggest that a proportion of L2 can co-localize with vesicular-bound TSG101 even when L2 is not part of the viral capsid. Whether this might have any relevance for the normal function of TSG101 and, likewise, whether this might have a role during other phases of the viral life cycle, remains to be determined. One of the major functions of TSG101 is to bind monoubiquitinated proteins and thereby prevent further ubiquitination from taking place (Burgdorf et al., 2004) . In HEK293 cells, polyubiquitination of HPV-16 L2 is easily detectable, although there does not seem to be any significant degree of proteasomal degradation. In the presence of TSG101, however, there is a dramatic reduction in the levels of L2 polyubiquitination, with only one species of L2 being co-immunoprecipitated with ubiquitin in the presence of TSG101, suggesting that this is a monoubiquitinated form of L2. Whether this activity of TSG101 is relevant for viral infection or, alternatively, is related to the later stages of viral infection, before L2 is complexed with L1 in the assembly of new virions, remains to be determined.
Taken together these studies provide compelling evidence of a functionally significant interaction between HPV-16 L2 and the ESCRT-1 component, TSG101. This interaction can modulate the localisation of L2 within the cell, and furthermore can reduce the levels of L2 polyubiquitination. Most importantly, TSG101 plays an important role in the PV infection process. Whether this reflects a general perturbation of late endosome maturation and MVB formation upon the loss of TSG101 expression, and subsequent alteration in the fate of the infecting virions (Doyotte et al., 2005; Razi and Futter, 2006; Bache et al., 2006) , or is a direct consequence of TSG101 affecting the sorting of L2-DNA complexes remains to be determined.
Materials and methods
Plasmids
The pCA plasmid expressing HPV-16 L2 protein has been described previously (Bergant-Marušič et al., 2012) . Deletion mutants of HPV-16 L2 protein were generated using the Invitrogen GeneTailor system and verified by sequencing. Oligonucleotides were designed in-house and were synthesized by MWG Biotech AG.
GST HPV-16 L1, GST HPV-16 L2, GST BPV-1 L2, GST SfPV-1 L2 and GST HPV-11 L2 as well as BPV-1, HPV-16 and MCV capsid protein expression plasmids have been described previously (Bergant and Banks, 2013) , as was the HA-tagged ubiquitin expression plasmid (Tomaićet al., 2011) .
Antibodies
The following primary antibodies were used in these studies: mouse anti-TSG101 (C2; Santa Cruz Biotechnology), mouse anti-HPV-16 L2 (2JGmab no. 5, Santa Cruz Biotechnology), rabbit anti-HPV-16 L2 (kindly provided by Martin Müller), mouse anti-HA (Roche), rabbit anti-alpha-actinin (H-300; Santa Cruz Biotechnology) and appropriate secondary antibodies conjugated to horseradish peroxidase (HRP; Dako) or rhodamine (Molecular Probes).
Cells and transfections
HEK293 (human embryonic kidney cells), U2OS (human osteosarcoma cells), HaCaT (spontaneously immortalized human keratinocyte cells) and 293TT cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin (100 U/mL) and glutamine (300 mg/mL). For transient siRNA experiments, cells were transfected using RNAiMAX (Invitrogen) with siRNA against TSG101 (ON-TARGETplus SMARTpool), and siRNA against HPV-18 E6/E7 (5_CAUUUACCAGCCCGACGAG, Dharmacon) as a control. For binding/coimmunoprecipitation assays cells were transfected with DNA constructs using either calcium phosphate (Ca 2 PO4) precipitation (Graham and van der Eb, 1973) for HEK293, 293TT and U2OS or PEI for HaCaTs. Fusion protein purification and binding assays GST-tagged fusion proteins were expressed and purified as described previously (Thomas et al., 1996) . TSG101 protein was translated in vitro using a Promega TNT kit and radiolabelled with [ 35 S] methionine (Perkin Elmer). Equal amounts of in vitro translated proteins were added to GST fusion proteins bound to glutathione agarose (Sigma) and incubated for 2 h at room temperature. After extensive washing with E1A buffer (25 mM HEPES, pH 7.0, 0.1% NP-40, 150 mM NaCl) bound proteins were analyzed by SDS-PAGE and autoradiography.
Cellular protein extracts for use in GST pull-down assays were generated using RIPA lysis buffer containing protease inhibitor cocktail set I (Calbiochem). These were used in GST pull-down assays as described above and, after extensive washing with E1A buffer, the bound proteins were detected using SDS-PAGE and Western blotting.
Coimmunoprecipitation
Cells were transfected with plasmids expressing GFP-tagged TSG101 and FLAG-HA-tagged HPV-16 L2 expression plasmids. After 24 h the cells were extracted with RIPA lysis buffer, and extracts then incubated with anti-HA conjugated agarose beads (Sigma) for 2 h on a rotating wheel at room temperature. The beads were extensively washed with E1A buffer and the immunoprecipitates were analyzed for TSG101 by SDS-PAGE and Western blotting using anti-TSG101 antibody.
Immunofluorescence
HaCaT cells were transfected with FLAG-HA-tagged HPV-16 L2 expression plasmids and a GFP-tagged TSG101 expression plasmid. After 24 h transfected cells were washed twice with phosphatebuffered saline (PBS), fixed with 4% paraformaldehyde in PBS for 15 min, washed again, and permeabilized in 0.1% Triton X-100 for 5 min. Cells were incubated with a mouse anti-HA antibody (Roche) for 2 h at 37 1C, washed extensively with PBS, and incubated for 20 min at 37 1C with rhodamine-conjugated goat anti-mouse antibody (Molecular Probes). Slides were washed, mounted in Vectashield mounting medium (VectorLaboratories) and analyzed using a Zeiss LSM510 confocal microscope with two lasers giving excitation lines at 480 nm and 510 nm. The data were collected with a 60 Â objective oil immersion lens.
Pseudovirion (PsV) production
HPV-16, BPV-1 and MCV PsVs containing a luciferase reporter plasmid were generated in 293TT cells as previously described (Buck et al., 2005; Smith et al., 2005) .
Infectivity assays
HaCaT cells were seeded in 12-well plates at a density 0.5 Â 10 5 /well (DNA transfection) or 0.3 Â 10 5 /well (siRNA transfection). 24 h (DNA transfection) or 72 h (siRNA) after transfection, PsVs were added at a concentration of 12 ng/mL. Infection was monitored at 48 h by luminometric analysis of firefly luciferase activity using the Luciferase Assay System kit (Promega). For each type of PsV, infection was normalized to 100% as the value obtained with cells transfected with control siRNA, and this was used to calculate the percentage reduction following transfection of the cells with TSG101 siRNA.
Ubiquitination assay
HEK293 cells were transfected with GFP-tagged HPV-16 L2, GFP-tagged TSG101 and HA-tagged ubiquitin. After 24 h cells were either treated with MG132 (Sigma) to rescue any proteins from proteasome mediated degradation, or left untreated. Cells were lysed and incubated with anti-HA conjugated agarose beads. After extensive washing the bound proteins were detected using SDS-PAGE and Western blotting.
